Stanley Nattel

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5060149/stanley-nattel-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

583 papers	48,791 citations	117 h-index	201 g-index
714 ext. papers	56,708 ext. citations	8.5 avg, IF	7.72 L-index

#	Paper	IF	Citations
583	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS Score: Insights From the BRAIN-AF Trial.. *Circulation: Arrhythmia and Electrophysiology*, **2022**, CIRCEP121010462	6.4	0
582	The role of cellular senescence in cardiac disease: basic biology and clinical relevance. *Nature Reviews Cardiology*, **2021**,	14.8	9
581	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. *Cardiovascular Research*, **2021**, 117, 1776-1789	9.9	13
580	Postoperative Atrial Fibrillation: Features, Mechanisms, and Clinical Management. *Cardiac Electrophysiology Clinics*, **2021**, 13, 123-132	1.4	3
579	Biomarkers in Atrial Fibrillation: Pathogenesis and Clinical Implications. *Cardiac Electrophysiology Clinics*, **2021**, 13, 221-233	1.4	5
578	Implications of Inflammation and Fibrosis in Atrial Fibrillation Pathophysiology. *Cardiac Electrophysiology Clinics*, **2021**, 13, 25-35	1.4	12
577	New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation. *Cardiovascular Research*, **2021**, 117, 1645-1661	9.9	5
576	Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it. *Cardiovascular Research*, **2021**, 117, 1616-1631	9.9	5
575	Sleep Apnea and Atrial Fibrillation. *Cardiac Electrophysiology Clinics*, **2021**, 13, 87-94	1.4	3
574	Inositol Trisphosphate Receptors and Nuclear Calcium in Atrial Fibrillation. *Circulation Research*, **2021**, 128, 619-635	15.7	6
573	Computational models of atrial fibrillation: achievements, challenges, and perspectives for improving clinical care. *Cardiovascular Research*, **2021**, 117, 1682-1699	9.9	11
572	Finding a new job: glutamate signaling acts in atrial cardiomyocytes. *Cell Research*, **2021**, 31, 943-944	24.7	1
571	Cohesin-protein Shugoshin-1 controls cardiac automaticity via HCN4 pacemaker channel. *Nature Communications*, **2021**, 12, 2551	17.4	1
570	Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation. *Cardiovascular Research*, **2021**, 117, 1609-1611	9.9	1
569	A computational model of pig ventricular cardiomyocyte electrophysiology and calcium handling: Translation from pig to human electrophysiology. *PLoS Computational Biology*, **2021**, 17, e1009137	5	1
568	Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines. *Canadian Journal of Cardiology*, **2021**, 37, 1607-1618	3.8	9
567	Ageing, comorbidities, and the complex determinants of atrial fibrillation in athletes. *European Heart Journal*, **2021**, 42, 3526-3528	9.5	1

566	Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling. *Cardiovascular Research*, **2021**, 117, 462-471	9.9	10
565	Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. *European Heart Journal*, **2021**, 42, 532-540	9.5	13
564	The effects of cardiac stretch on atrial fibroblasts: Analysis of the evidence and potential role in atrial fibrillation. *Cardiovascular Research*, **2021**,	9.9	1
563	Does gut microbiota affect atrial rhythm? Causalities and speculations. *European Heart Journal*, **2021**, 42, 3521-3525	9.5	3
562	Electrophysiological engineering of heart-derived cells with calcium-dependent potassium channels improves cell therapy efficacy for cardioprotection. *Nature Communications*, **2021**, 12, 4963	17.4	1
561	Transcriptomic Profiling of Canine Atrial Fibrillation Models After One Week of Sustained Arrhythmia. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e009887	6.4	1
560	Atrial-Specific LKB1 Knockdown Represents a Novel Mouse Model of Atrial Cardiomyopathy With Spontaneous Atrial Fibrillation. *Circulation*, **2021**, 144, 909-912	16.7	2
559	Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. *Cardiovascular Research*, **2021**,	9.9	6
558	Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation. *Circulation Research*, **2021**, 129, 804-820	15.7	2
557	Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. *Nature*, **2020**, 587, 460-465	50.4	19
556	Pulmonary Vein Stenosis After Atrial Fibrillation Ablation: Insights From the ADVICE Trial. *Canadian Journal of Cardiology*, **2020**, 36, 1965-1974	3.8	5
555	Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective. *Circulation Research*, **2020**, 127, 51-72	15.7	87
554	Prevalence and clinical impact of spontaneous and adenosine-induced pulmonary vein reconduction in the Contact-Force vs. Cryoballoon Atrial Fibrillation Ablation (CIRCA-DOSE) study. *Heart Rhythm*, **2020**, 17, 897-904	6.7	4
553	Physical activity and atrial fibrillation risk: it's complicated; and sex is critical. *European Heart Journal*, **2020**, 41, 1487-1489	9.5	8
552	Linking cellular energy state to atrial fibrillation pathogenesis: Potential role of adenosine monophosphate-activated protein kinase. *Heart Rhythm*, **2020**, 17, 1398-1404	6.7	5
551	Altered calcium handling produces reentry-promoting action potential alternans in atrial fibrillation-remodeled hearts. *JCI Insight*, **2020**, 5,	9.9	12
550	Binge Alcohol Exposure Triggers Atrial Fibrillation Through T-Type Ca Channel Upregulation via Protein Kinase C (PKC) / Glycogen Synthesis Kinase 3β (GSK3β) / Nuclear Factor of Activated T-Cells (NFAT) Signaling - An Experimental Account of Holiday Heart Syndrome. *Circulation Journal*, **2020**, 84, 1931-1940	2.9	6
549	Reply: Could Different Thresholds for Tachycardic-Induced Atrial Myopathy Reflect Different Rates Between Atrial Fibrillation and Flutter?. *Journal of the American College of Cardiology*, **2020**, 76, 2179-2180	15.1	

548	Comparison of Atrial Remodeling Caused by Sustained Atrial Flutter Versus Atrial Fibrillation. *Journal of the American College of Cardiology*, **2020**, 76, 374-388	15.1	9
547	Association of Atrial Fibrillation Episode Duration With Arrhythmia Recurrence Following Ablation: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Network Open*, **2020**, 3, e208748	10.4	14
546	Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation. *Circulation Research*, **2020**, 127, 1036-1055	15.7	43
545	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. *Canadian Journal of Cardiology*, **2020**, 36, 1847-1948	3.8	82
544	M/M/Infinity Birth-Death Processes - A Quantitative Representational Framework to Summarize and Explain Phase Singularity and Wavelet Dynamics in Atrial Fibrillation. *Frontiers in Physiology*, **2020**, 11, 616866	4.6	7
543	Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease. *Journal of the American College of Cardiology*, **2019**, 74, 1332-1347	15.1	28
542	Role of the lysyl oxidase enzyme family in cardiac function and disease. *Cardiovascular Research*, **2019**, 115, 1820-1837	9.9	17
541	Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF- Signaling and Epigenomics. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 7, 411-431	7.9	6
540	An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. *Cardiovascular Research*, **2019**, 115, 1975-1985	9.9	8
539	Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria. *Europace*, **2019**, 21, 1261-1269	3.9	7
538	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. *Canadian Journal of Cardiology*, **2019**, 35, 1069-1077	3.8	16
537	Computational models of the atrial fibrillation substrate: can they explain post-ablation recurrences and help to prevent them. *Cardiovascular Research*, **2019**, 115, 1681-1683	9.9	1
536	Clinical Relevance of Functional Models of Atrial Reentry and Fibrillation **2019**, 473-481		
535	Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling. *Cardiovascular Research*, **2019**, 115, 94-106	9.9	21
534	The Inability of the Choroid to Revascularize in Oxygen-Induced Retinopathy Results from Increased p53/miR-Let-7b Activity. *American Journal of Pathology*, **2019**, 189, 2340-2356	5.8	6
533	Postoperative atrial fibrillation: mechanisms, manifestations and management. *Nature Reviews Cardiology*, **2019**, 16, 417-436	14.8	106
532	Renewal Theory as a Universal Quantitative Framework to Characterize Phase Singularity Regeneration in Mammalian Cardiac Fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2019**, 12, e007569	6.4	17
531	Role of autonomic nervous system in atrial fibrillation. *International Journal of Cardiology*, **2019**, 287, 181-188	3.2	41

530	Clarity and controversy around rate control in AF, the orphan child in AF therapeutics. *International Journal of Cardiology*, **2019**, 287, 189-194	3.2	1
529	Translational Challenges in Atrial Fibrillation. *Circulation Research*, **2018**, 122, 752-773	15.7	74
528	Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells. *Journal of Physiology*, **2018**, 596, 2359-2379	3.9	12
527	Response by Lau et al to Letters Regarding Article, "Modifiable Risk Factors and Atrial Fibrillation". *Circulation*, **2018**, 137, 1534-1535	16.7	1
526	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Europace*, **2018**, 20, e1-e160	3.9	461
525	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. *Europace*, **2018**, 20, 157-208	3.9	227
524	Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review. *JAMA Cardiology*, **2018**, 3, 532-540	16.2	133
523	Atrial Infarction-Induced Spontaneous Focal Discharges and Atrial Fibrillation in Sheep: Role of Dantrolene-Sensitive Aberrant Ryanodine Receptor Calcium Release. *Circulation: Arrhythmia and Electrophysiology*, **2018**, 11, e005659	6.4	13
522	The Molecular Pathophysiology of Atrial Fibrillation **2018**, 396-408		
521	Mechanisms and Clinical Significance of Arrhythmia-Induced Cardiomyopathy. *Canadian Journal of Cardiology*, **2018**, 34, 1449-1460	3.8	17
520	Taking the Pulse of Atrial Fibrillation: A Practical Approach to Rate Control. *Canadian Journal of Cardiology*, **2018**, 34, 1526-1530	3.8	6
519	Prof Niels Voigt talks to Prof Stanley Nattel about advances in atrial fibrillation research and career insights. *Cardiovascular Research*, **2018**, 114, e65	9.9	
518	Age as a Critical Determinant of Atrial Fibrillation: A Two-sided Relationship. *Canadian Journal of Cardiology*, **2018**, 34, 1396-1406	3.8	21
517	Application of kinomic array analysis to screen for altered kinases in atrial fibrillation remodeling. *Heart Rhythm*, **2018**, 15, 1708-1716	6.7	4
516	Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation. *Frontiers in Physiology*, **2018**, 9, 1383	4.6	39
515	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. *Canadian Journal of Cardiology*, **2018**, 34, 1371-1392	3.8	144
514	Catheter ablation of atrial fibrillation and outcomes in heart failure patients: seeking the treasure in the CASTLE. *Cardiovascular Research*, **2018**, 114, e50-e52	9.9	1
513	Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. *Circulation*, **2018**, 138, 2227-2242	16.7	174

512	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. *Heart Rhythm*, **2017**, 14, e3-e40	6.7	138
511	MicroRNA-135a regulates sodium-calcium exchanger gene expression and cardiac electrical activity. *Heart Rhythm*, **2017**, 14, 739-748	6.7	7
510	Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion. *Journal of the American Heart Association*, **2017**, 6,	6	36
509	Rate-Dependent Role of I in Human Atrial Repolarization and Atrial Fibrillation Maintenance. *Biophysical Journal*, **2017**, 112, 1997-2010	2.9	13
508	Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. *JACC: Clinical Electrophysiology*, **2017**, 3, 425-435	4.6	167
507	Characterization of Sgo1 expression in developing and adult mouse. *Gene Expression Patterns*, **2017**, 25-26, 36-45	1.5	6
506	Controversies About Atrial Fibrillation Mechanisms: Aiming for Order in Chaos and Whether it Matters. *Circulation Research*, **2017**, 120, 1396-1398	15.7	49
505	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. *Canadian Journal of Cardiology*, **2017**, 33, 965-976	3.8	68
504	Demystifying rotors and their place in clinical translation of atrial fibrillation mechanisms. *Nature Reviews Cardiology*, **2017**, 14, 509-520	14.8	55
503	Endoplasmic Reticulum Stress Is Associated With Autophagy and Cardiomyocyte Remodeling in Experimental and Human Atrial Fibrillation. *Journal of the American Heart Association*, **2017**, 6,	6	63
502	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. *Journal of Arrhythmia*, **2017**, 33, 369-409	1.5	148
501	Basic Electrophysiology. *Cardiovascular Medicine*, **2017**, 1-13	0.1	
500	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *Journal of Interventional Cardiac Electrophysiology*, **2017**, 50, 1-55	2.4	58
499	A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications. *Canadian Journal of Cardiology*, **2017**, 33, 1577-1586	3.8	10
498	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. *Heart Rhythm*, **2017**, 14, e445-e494	6.7	72
497	Dataset of expression in cardiac, gastrointestinal, hepatic and neuronal tissue in mouse. *Data in Brief*, **2017**, 13, 731-737	1.2	4
496	Atrial Cardiomyopathy: A Useful Notion in Cardiac Disease Management or a Passing Fad?. *Journal of the American College of Cardiology*, **2017**, 70, 756-765	15.1	90
495	JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. *Cardiovascular Research*, **2017**, 113, 310-320	9.9	28

494	Modifiable Risk Factors and Atrial Fibrillation. *Circulation*, **2017**, 136, 583-596	16.7	263
493	Dysfunction of Myosin Light-Chain 4 (MYL4) Leads to Heritable Atrial Cardiomyopathy With Electrical, Contractile, and Structural Components: Evidence From Genetically-Engineered Rats. *Journal of the American Heart Association*, **2017**, 6,	6	26
492	Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw. *Canadian Journal of Cardiology*, **2017**, 33, 283-286	3.8	22
491	Metabolic Considerations in Atrial Fibrillation - Mechanistic Insights and Therapeutic Opportunities. *Circulation Journal*, **2017**, 81, 1749-1757	2.9	28
490	Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. *European Heart Journal*, **2016**, 37, 640-50	9.5	35
489	Redefining the Blanking Period After Catheter Ablation for Paroxysmal Atrial Fibrillation: Insights From the ADVICE (Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination) Trial. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,	6.4	61
488	Atrial fibrillation. *Nature Reviews Disease Primers*, **2016**, 2, 16016	51.1	115
487	Arrhythmias in 2015: Advances in drug, ablation, and device therapy for cardiac arrhythmias. *Nature Reviews Cardiology*, **2016**, 13, 67-8	14.8	5
486	The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. *Cardiovascular Research*, **2016**, 109, 467-79	9.9	108
485	Caged ligands to study the role of intracellular GPCRs. *Methods*, **2016**, 92, 72-7	4.6	8
484	Computational models of atrial cellular electrophysiology and calcium handling, and their role in atrial fibrillation. *Journal of Physiology*, **2016**, 594, 537-53	3.9	34
483	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. *Europace*, **2016**, 18, 1455-1490	3.9	268
482	The pioneering work of George Mines on cardiac arrhythmias: groundbreaking ideas that remain influential in contemporary cardiac electrophysiology. *Journal of Physiology*, **2016**, 594, 2377-86	3.9	7
481	A novel transgenic rabbit model with reduced repolarization reserve: long QT syndrome caused by a dominant-negative mutation of the KCNE1 gene. *British Journal of Pharmacology*, **2016**, 173, 2046-61	8.6	29
480	Potassium Channel Remodeling in Heart Disease. *Cardiac Electrophysiology Clinics*, **2016**, 8, 337-47	1.4	5
479	Dronedarone: Basic Pharmacology and Clinical Use. *Cardiac Electrophysiology Clinics*, **2016**, 8, 453-65	1.4	10
478	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. *Journal of Arrhythmia*, **2016**, 32, 247-78	1.5	59
477	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. *Canadian Journal of Cardiology*, **2016**, 32, 1170-1185	3.8	212

476	Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. *Nature Reviews Cardiology*, **2016**, 13, 575-90	14.8	89
475	A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation: Shedding New Light on the Effects of Catheter Ablation. *JACC: Clinical Electrophysiology*, **2015**, 1, 105-115	4.6	43
474	Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. *Lancet, The*, **2015**, 386, 672-9	40	146
473	Wavelet analysis of cardiac optical mapping data. *Computers in Biology and Medicine*, **2015**, 65, 243-55	7	8
472	Loss of cardiomyocyte integrin-linked kinase produces an arrhythmogenic cardiomyopathy in mice. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 921-32	6.4	14
471	Atrial Fibrillation Activates AMP-Dependent Protein Kinase and its Regulation of Cellular Calcium Handling: Potential Role in Metabolic Adaptation and Prevention of Progression. *Journal of the American College of Cardiology*, **2015**, 66, 47-58	15.1	54
470	Nestin is a marker of lung remodeling secondary to myocardial infarction and type I diabetes in the rat. *Journal of Cellular Physiology*, **2015**, 230, 170-9	7	12
469	The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2015**, 388, 973-81	3.4	2
468	Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade. *Circulation*, **2015**, 132, 2203-11	16.7	33
467	Photoreleasable ligands to study intracrine angiotensin II signalling. *Journal of Physiology*, **2015**, 593, 521-39	3.9	11
466	MicroRNAs and atrial fibrillation: mechanisms and translational potential. *Nature Reviews Cardiology*, **2015**, 12, 80-90	14.8	92
465	Role of inflammation in atrial fibrillation pathophysiology and management. *Circulation Journal*, **2015**, 79, 495-502	2.9	251
464	The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy. *Journal of Cardiovascular Pharmacology*, **2015**, 66, 432-40	3.1	9
463	Pulmonary vein exit block despite recovery of entry conduction during redo-ablation for atrial fibrillation. *Europace*, **2015**, 17, 752	3.9	2
462	Modeling the aging heart: from local respiratory defects to global rhythm disturbances. *Cell Metabolism*, **2015**, 21, 662-3	24.6	1
461	Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 769-82	2.5	4
460	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. *Canadian Journal of Cardiology*, **2015**, 31, 1207-18	3.8	36
459	Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling. *Circulation Research*, **2015**, 116, 836-45	15.7	64

458	Isolation and study of cardiac nuclei from canine myocardium and adult ventricular myocytes. *Methods in Molecular Biology*, **2015**, 1234, 69-80	1.4	5
457	Lone atrial fibrillation: does it exist?. *Journal of the American College of Cardiology*, **2014**, 63, 1715-23	15.1	125
456	Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. *Journal of the American College of Cardiology*, **2014**, 63, 2335-45	15.1	375
455	Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circulation Research*, **2014**, 114, 1500-15	15.7	389
454	Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. *Circulation Research*, **2014**, 114, 1483-99	15.7	373
453	Fibroblast electrical remodeling in heart failure and potential effects on atrial fibrillation. *Biophysical Journal*, **2014**, 107, 2444-55	2.9	28
452	Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. *Journal of the American College of Cardiology*, **2014**, 64, 2013-23	15.1	128
451	Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling. *Journal of Molecular and Cellular Cardiology*, **2014**, 77, 113-24	5.8	36
450	Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: potential significance in arrhythmogenesis and antiarrhythmic therapy. *Heart Rhythm*, **2014**, 11, 2092-100	6.7	20
449	Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. *Journal of the American College of Cardiology*, **2014**, 64, 1441-8	15.1	62
448	Decade in review--arrhythmias: Cardiac fibrillation--challenges and evolving solutions. *Nature Reviews Cardiology*, **2014**, 11, 626-7	14.8	3
447	Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. *Circulation*, **2014**, 129, 145-156	16.7	273
446	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. *Journal of the American Heart Association*, **2014**, 3,	6	33
445	The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. *Circulation Research*, **2014**, 114, 1453-68	15.7	587
444	F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2014**, 387, 667-77	3.4	7
443	Sex differences in cardiac electrophysiology and clinical arrhythmias: epidemiology, therapeutics, and mechanisms. *Canadian Journal of Cardiology*, **2014**, 30, 783-92	3.8	73
442	MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. *Circulation Research*, **2014**, 114, 689-705	15.7	93
441	Atrial fibrillation ablation: translating basic mechanistic insights to the patient. *Journal of the American College of Cardiology*, **2014**, 64, 823-31	15.1	58

440	Exchange protein directly activated by cAMP mediates slow delayed-rectifier current remodeling by sustained □-adrenergic activation in guinea pig hearts. *Circulation Research*, **2014**, 114, 993-1003	15.7	38
439	Increasing appreciation for the role of single-pill combinations for the prevention of atherosclerotic disease: a pro-polypill polemic. *Canadian Journal of Cardiology*, **2014**, 30, 517-9	3.8	2
438	Early management of atrial fibrillation to prevent cardiovascular complications. *European Heart Journal*, **2014**, 35, 1448-56	9.5	128
437	Disease and region-related cardiac fibroblast potassium current variations and potential functional significance. *Cardiovascular Research*, **2014**, 102, 487-96	9.9	14
436	Regional ion channel gene expression heterogeneity and ventricular fibrillation dynamics in human hearts. *PLoS ONE*, **2014**, 9, e82179	3.7	16
435	2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *Canadian Journal of Cardiology*, **2014**, 30, 1114-30	3.8	305
434	Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. *Circulation*, **2014**, 129, 1276-1285	16.7	114
433	Activation of histone deacetylase-6 induces contractile dysfunction through derailment of □-tubulin proteostasis in experimental and human atrial fibrillation. *Circulation*, **2014**, 129, 346-58	16.7	97
432	Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. *Circulation*, **2014**, 129, 430-40	16.7	123
431	Pulmonary vein isolation using "contact force" ablation: the effect on dormant conduction and long-term freedom from recurrent atrial fibrillation--a prospective study. *Heart Rhythm*, **2014**, 11, 1919-24	6.7	116
430	New directions in cardiac arrhythmia management: present challenges and future solutions. *Canadian Journal of Cardiology*, **2014**, 30, S420-30	3.8	21
429	A look into the future of cardiology: perspectives from the Montreal Heart Institute. *Canadian Journal of Cardiology*, **2014**, 30, S399-400	3.8	
428	Inefficacy of a highly selective T-type calcium channel blocker in preventing atrial fibrillation related remodeling. *Journal of Cardiovascular Electrophysiology*, **2014**, 25, 531-536	2.7	2
427	Atrial fibrillation compendium: historical context and detailed translational perspective on an important clinical problem. *Circulation Research*, **2014**, 114, 1447-52	15.7	22
426	The Molecular Pathophysiology of Atrial Fibrillation **2014**, 449-458		0
425	Reply: Of mice and men: atrial fibrillation in veteran endurance runners. *Journal of the American College of Cardiology*, **2014**, 63, 89-90	15.1	1
424	Cholinergic and Constitutive Regulation of Atrial Potassium Channel **2014**, 383-391		
423	Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca□+ in adult cardiac myocytes. *Journal of Molecular and Cellular Cardiology*, **2013**, 62, 189-202	5.8	36

422	Electrical storm: recent pathophysiological insights and therapeutic consequences. *Basic Research in Cardiology*, **2013**, 108, 336	11.8	24
421	Region-specific gene expression profiles in the left atria of patients with valvular atrial fibrillation. *Heart Rhythm*, **2013**, 10, 383-91	6.7	40
420	Unique quantitative trait loci in synergy permanently improve diastolic dysfunction. *Canadian Journal of Cardiology*, **2013**, 29, 1302-9	3.8	2
419	Corticosteroid use during pulmonary vein isolation is associated with a higher prevalence of dormant pulmonary vein conduction. *Heart Rhythm*, **2013**, 10, 1569-75	6.7	14
418	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. *Journal of the American College of Cardiology*, **2013**, 62, 1596-606	15.1	88
417	Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential. *Journal of Physiology*, **2013**, 591, 1409-32	3.9	88
416	MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. *Circulation*, **2013**, 127, 1466-75, 1475e1-28	16.7	178
415	Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. *Journal of the American College of Cardiology*, **2013**, 62, 68-77	15.1	185
414	Regulation of cardiac nitric oxide signaling by nuclear β-adrenergic and endothelin receptors. *Journal of Molecular and Cellular Cardiology*, **2013**, 62, 58-68	5.8	36
413	Late pulmonary vein reconnection: insights into mechanisms of atrial fibrillation recurrence after pulmonary vein isolation. *Europace*, **2013**, 15, 1143	3.9	57
412	T-type calcium current contributes to escape automaticity and governs the occurrence of lethal arrhythmias after atrioventricular block in mice. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 799-808	6.4	17
411	Unique cardiac Purkinje fiber transient outward current β-subunit composition: a potential molecular link to idiopathic ventricular fibrillation. *Circulation Research*, **2013**, 112, 1310-22	15.7	61
410	Nicotinamide adenine dinucleotide phosphate oxidase 4 mediates the differential responsiveness of atrial versus ventricular fibroblasts to transforming growth factor-β. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 790-8	6.4	34
409	Pulmonary vein isolation using a pace-capture-guided versus an adenosine-guided approach: effect on dormant conduction and long-term freedom from recurrent atrial fibrillation--a prospective study. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 1103-8	6.4	33
408	Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation **2013**, 333-352		
407	Adenosine testing in atrial flutter ablation: unmasking of dormant conduction across the cavotricuspid isthmus and risk of recurrence. *Journal of Cardiovascular Electrophysiology*, **2013**, 24, 995-1001	2.7	18
406	Rebuttal from Eduard Guasch and Stanley Nattel. *Journal of Physiology*, **2013**, 591, 4947	3.9	
405	CrossTalk proposal: Prolonged intense exercise training does lead to myocardial damage. *Journal of Physiology*, **2013**, 591, 4939-41	3.9	14

404	Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. *Journal of Physiology*, **2013**, 591, 4189-206	3.9	94
403	A clinical approach to early repolarization. *Circulation*, **2013**, 127, 1620-9	16.7	30
402	Nuclear factor of activated T cells mediates RhoA-induced fibronectin upregulation in glomerular podocytes. *American Journal of Physiology - Renal Physiology*, **2013**, 304, F849-62	4.3	10
401	Combining distinctive and novel loci doubles BP reduction, reverses diastolic dysfunction and mitigates LV hypertrophy. *Journal of Hypertension*, **2013**, 31, 927-35	1.9	4
400	Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. *PLoS ONE*, **2013**, 8, e55427	3.7	36
399	MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. *Journal of Clinical Investigation*, **2013**, 123, 1939-51	15.9	183
398	Antiarrhythmic drugs and strategies **2013**, 272-331		2
397	Novel molecular targets for atrial fibrillation therapy. *Nature Reviews Drug Discovery*, **2012**, 11, 275-91	64.1	140
396	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Europace*, **2012**, 14, 528-606	3.9	1160
395	Calcium handling and atrial fibrillation. *Wiener Medizinische Wochenschrift*, **2012**, 162, 287-91	2.9	21
394	Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: a comparative multicenter study. *Heart Rhythm*, **2012**, 9, 1025-30	6.7	47
393	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in	6.7	1314
392	Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. *Heart Rhythm*, **2012**, 9, 1409-16.e1SC) and the E. *Heart Rhythm*, **2012**, 9, 632-696.e21	6.7	79
391	The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. *European Heart Journal*, **2012**, 33, 1870-7	9.5	128
390	Hypoxia in early life is associated with lasting changes in left ventricular structure and function at maturity in the rat. *International Journal of Cardiology*, **2012**, 156, 165-73	3.2	8
389	Adenosine following pulmonary vein isolation to target dormant conduction elimination (ADVICE): methods and rationale. *Canadian Journal of Cardiology*, **2012**, 28, 184-90	3.8	44
388	Canadian Journal of Cardiology: A Year of Change. *Canadian Journal of Cardiology*, **2012**, 28, 5	3.8	2
387	Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. *Canadian Journal of Cardiology*, **2012**, 28, 125-36	3.8	389

386	G protein-coupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. *Journal of Physiology*, **2012**, 590, 1313-30	3.9	101
385	Triggering of cardiac arrhythmic events in long QT syndrome: lessons from funny bunnies. *Journal of Physiology*, **2012**, 590, 1311-2	3.9	6
384	Remodeling and Reverse Remodeling: Mapping/Imaging Findings **2012**, 788-796		
383	A proposal for new clinical concepts in the management of atrial fibrillation. *American Heart Journal*, **2012**, 164, 292-302.e1	4.9	39
382	In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics. *Biophysical Journal*, **2012**, 102, 951-60	2.9	24
381	Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 1027-35	6.4	136
380	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Journal of Interventional Cardiac Electrophysiology*, **2012**, 33, 171-257	2.4	250
379	Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. *Circulation*, **2012**, 126, 2051-64	16.7	185
378	Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 1168-75	6.4	11
377	Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation*, **2012**, 125, 2059-70	16.7	395
376	AMP-activated protein kinase: potential role in cardiac electrophysiology and arrhythmias. *Circulation: Arrhythmia and Electrophysiology*, **2012**, 5, 860-7	6.4	29
375	Congestive heart failure effects on atrial fibroblast phenotype: differences between freshly-isolated and cultured cells. *PLoS ONE*, **2012**, 7, e52032	3.7	30
374	Proarrhythmic atrial calcium cycling in the diseased heart. *Advances in Experimental Medicine and Biology*, **2012**, 740, 1175-91	3.6	11
373	Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: a clinical-experimental correlation. *Heart Rhythm*, **2011**, 8, 1426-33	6.7	39
372	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. *Canadian Journal of Cardiology*, **2011**, 27, 47-59	3.8	84
371	Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. *Cardiovascular Research*, **2011**, 89, 744-53	9.9	244
370	Minimum Information about a Cardiac Electrophysiology Experiment (MICEE): standardised reporting for model reproducibility, interoperability, and data sharing. *Progress in Biophysics and Molecular Biology*, **2011**, 107, 4-10	4.7	45
369	Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. *Circulation*, **2011**, 123, 13-22	16.7	298

368	Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. *Cardiovascular Research*, **2011**, 91, 420-8	9.9	15
367	The role of pulmonary veins vs. autonomic ganglia in different experimental substrates of canine atrial fibrillation. *Cardiovascular Research*, **2011**, 89, 825-33	9.9	49
366	Impact of tissue geometry on simulated cholinergic atrial fibrillation: a modeling study. *Chaos*, **2011** , 21, 013108	3.3	16
365	Differential protein kinase C isoform regulation and increased constitutive activity of acetylcholine-regulated potassium channels in atrial remodeling. *Circulation Research*, **2011**, 109, 1031-43	15.7	69
364	Role of KATP channels in the maintenance of ventricular fibrillation in cardiomyopathic human hearts. *Circulation Research*, **2011**, 109, 1309-18	15.7	36
363	Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. *Circulation*, **2011**, 123, 137-46	16.7	113
362	Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. *Circulation*, **2011**, 123, 2192-203	16.7	43
361	Recent advances in the molecular pathophysiology of atrial fibrillation. *Journal of Clinical Investigation*, **2011**, 121, 2955-68	15.9	369
360	Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. *Cardiovascular Research*, **2011**, 92, 67-74	9.9	64
359	Transforming growth factor-□and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes. *Cardiovascular Research*, **2011**, 91, 62-70	9.9	54
358	Anthrax lethal factor activates K(+) channels to induce IL-1□secretion in macrophages. *Journal of Immunology*, **2011**, 186, 5236-43	5.3	12
357	Interactions between cardiac fibrosis spatial pattern and ionic remodeling on electrical wave propagation. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2011**, 2011, 4669-72	0.9	18
356	Atrial fibrillation pathophysiology: implications for management. *Circulation*, **2011**, 124, 2264-74	16.7	464
355	Concealed automaticity from an island of atrial myocardium post cavotricuspid ablation. *Journal of Cardiovascular Electrophysiology*, **2010**, 21, 1408-9	2.7	1
354	Exercise training, inflammation and heart failure: working out to cool down. *Journal of Physiology*, **2010**, 588, 2525-6	3.9	5
353	Physiological versus pathological cardiac electrical remodelling: potential basis and relevance to clinical management. *Journal of Physiology*, **2010**, 588, 4855-6	3.9	6
352	Sudden cardio arrest: when normal ECG variants turn lethal. *Nature Medicine*, **2010**, 16, 646-7	50.5	8
351	A high-fat diet increases risk of ventricular arrhythmia in female rats: enhanced arrhythmic risk in the absence of obesity or hyperlipidemia. *Journal of Applied Physiology*, **2010**, 108, 933-40	3.7	23

350	Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 530-41	6.4	83
349	Mechanisms by which adenosine restores conduction in dormant canine pulmonary veins. *Circulation*, **2010**, 121, 963-72	16.7	146
348	Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. *Journal of Biological Chemistry*, **2010**, 285, 22338-49	5.4	89
347	Animal models for atrial fibrillation: clinical insights and scientific opportunities. *Europace*, **2010**, 12, 160-72	3.9	112
346	Role of constitutively active acetylcholine-mediated potassium current in atrial contractile dysfunction caused by atrial tachycardia remodelling. *Europace*, **2010**, 12, 1490-7	3.9	7
345	Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2010**, 3, 472-80	6.4	154
344	Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. *Heart Rhythm*, **2010**, 7, 1862-9	6.7	42
343	Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. *Journal of the American College of Cardiology*, **2010**, 55, 1796-802	15.1	108
342	Clinical and mechanistic issues in early repolarization of normal variants and lethal arrhythmia syndromes. *Journal of the American College of Cardiology*, **2010**, 56, 1177-86	15.1	73
341	Roles of the left atrial roof and pulmonary veins in the anatomic substrate for persistent atrial fibrillation and ablation in a canine model. *Journal of the American College of Cardiology*, **2010**, 56, 1728-38	15.1	26
340	Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. *Drugs*, **2010**, 70, 573-603	12.1	52
339	Ion-channel mRNA-expression profiling: Insights into cardiac remodeling and arrhythmic substrates. *Journal of Molecular and Cellular Cardiology*, **2010**, 48, 96-105	5.8	29
338	Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. *Journal of Molecular and Cellular Cardiology*, **2010**, 49, 639-46	5.8	136
337	Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. *Journal of Molecular and Cellular Cardiology*, **2010**, 49, 851-63	5.8	69
336	New antiarrhythmic drugs for treatment of atrial fibrillation. *Lancet, The*, **2010**, 375, 1212-23	40	210
335	Voltage-clamp-based methods for the detection of constitutively active acetylcholine-gated I(K,ACh) channels in the diseased heart. *Methods in Enzymology*, **2010**, 484, 653-75	1.7	14
334	Dormant pulmonary vein conduction unmasked by external electrical cardioversion. *Heart Rhythm*, **2010**, 7, 1706-7	6.7	0
333	Mechanisms of lethal arrhythmias due to acute myocardial ischemia: regional factors and challenges in sudden death prevention. *Heart Rhythm*, **2010**, 7, 387-8	6.7	

332	Regulator of G-protein signalling 4 (RGS4) KO mice show increased susceptibility to atrial fibrillation. *FASEB Journal*, **2010**, 24, 855.1	0.9	
331	Transcriptional profiling of ion channel genes in Brugada syndrome and other right ventricular arrhythmogenic diseases. *European Heart Journal*, **2009**, 30, 487-96	9.5	38
330	Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. *Europace*, **2009**, 11, 860-85	3.9	84
329	Rate-dependence of atrial tachycardia effects on atrial refractoriness and atrial fibrillation maintenance. *Cardiovascular Research*, **2009**, 81, 90-7	9.9	19
328	Cardiac pathways distinguish two epistatic modules enacting BP quantitative trait loci and candidate gene analysis. *Hypertension Research*, **2009**, 32, 631-7	4.7	10
327	Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. *Circulation Research*, **2009**, 105, 1213-22	15.7	143
326	Stem cells are not proarrhythmic: letting the genie out of the bottle. *Circulation*, **2009**, 119, 1824-31	16.7	32
325	Ion channel subunit expression changes in cardiac Purkinje fibers: a potential role in conduction abnormalities associated with congestive heart failure. *Circulation Research*, **2009**, 104, 1113-22	15.7	40
324	The calcium/calmodulin/kinase system and arrhythmogenic afterdepolarizations in bradycardia-related acquired long-QT syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 295-304	6.4	48
323	Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. *Circulation*, **2009**, 119, 606-18	16.7	378
322	Funny current downregulation and sinus node dysfunction associated with atrial tachyarrhythmia: a molecular basis for tachycardia-bradycardia syndrome. *Circulation*, **2009**, 119, 1576-85	16.7	94
321	Association of neonatal hypoxia with lasting changes in left ventricular gene expression: an animal model. *Journal of Thoracic and Cardiovascular Surgery*, **2009**, 138, 538-46, 546.e1	1.5	15
320	Calcium-activated potassium current: a novel ion channel candidate in atrial fibrillation. *Journal of Physiology*, **2009**, 587, 1385-6	3.9	24
319	Fast and furious: new ways to think about, study and treat cardiac arrhythmias. *Journal of Physiology*, **2009**, 587, 1383-4	3.9	
318	Exercise training as a treatment for heart failure: potential mechanisms and clinical implications. *Journal of Physiology*, **2009**, 587, 5011-3	3.9	10
317	Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction. *PACE - Pacing and Clinical Electrophysiology*, **2009**, 32, 99-105	1.6	8
316	Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2009**, 46, 385-94	5.8	78
315	Novel approaches for pharmacological management of atrial fibrillation. *Drugs*, **2009**, 69, 757-74	12.1	58

314	Cell calcium, repolarization changes, and spontaneous postshock fibrillation in failing hearts: causes of refibrillation and electrical storm. *Heart Rhythm*, **2009**, 6, 793-5	6.7	1
313	Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. *Heart Rhythm*, **2009**, 6, 1802-9	6.7	184
312	Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. *Heart Rhythm*, **2009**, 6, 1465-72	6.7	23
311	Frequency-domain versus time-domain analysis: optimizing complex fractionated atrial electrogram identification for atrial fibrillation ablation. *Heart Rhythm*, **2009**, 6, 1483-4	6.7	
310	Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction. *Heart Rhythm*, **2009**, 6, 1792-801	6.7	31
309	G-protein signaling and arrhythmogenic atrial remodeling: relevance to novel therapeutic targets in atrial fibrillation. *Heart Rhythm*, **2009**, 6, 85-6	6.7	5
308	Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. *Current Opinion in Cardiology*, **2009**, 24, 50-5	2.1	31
307	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. *European Heart Journal*, **2009**, 30, 2969-77c	9.5	136
306	Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. *Cardiovascular Research*, **2009**, 81, 491-9	9.9	73
305	Experimental and Theoretical Insights into Fundamental Mechanisms of Antiarrhythmic Drug Actions on Atrial Fibrillation: Prospects for Improved Pharmacotherapy **2009**, 52-60		
304	Consequences of Atrial or Ventricular Tachypacing on the Heat Shock Proteins (HSP) level of Expression and Phosphorylation. *McGill Journal of Medicine*, **2009**, 12, 34		2
303	Delayed-rectifier potassium currents and the control of cardiac repolarization: Noble and Tsien 40 years after. *Journal of Physiology*, **2008**, 586, 5849-52	3.9	7
302	Model systems for the discovery and development of antiarrhythmic drugs. *Progress in Biophysics and Molecular Biology*, **2008**, 98, 328-39	4.7	27
301	Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. *Heart Rhythm*, **2008** , 5, 451-9	6.7	87
300	Atrial-selective approaches for the treatment of atrial fibrillation. *Journal of the American College of Cardiology*, **2008**, 51, 787-92	15.1	65
299	Molecular basis of funny current (If) in normal and failing human heart. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 289-99	5.8	133
298	Marked differences between atrial and ventricular gene-expression remodeling in dogs with experimental heart failure. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 821-31	5.8	29
297	Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 685-93	5.8	62

296	Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 707-8	5.8	6
295	Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. *Journal of the American College of Cardiology*, **2008**, 51, 802-9	15.1	849
294	Rhythm control versus rate control for atrial fibrillation and heart failure. *New England Journal of Medicine*, **2008**, 358, 2667-77	59.2	1090
293	Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF). *Canadian Journal of Cardiology*, **2008**, 24, 709-13	3.8	17
292	Cellular properties of C-terminal KCNH2 long QT syndrome mutations: description and divergence from clinical phenotypes. *Heart Rhythm*, **2008**, 5, 1159-67	6.7	4
291	Repolarization indices or calcium-current recovery/repolarization balance: what determines torsadogenesis?. *Heart Rhythm*, **2008**, 5, 280-1	6.7	1
290	To the Editor—Response. *Heart Rhythm*, **2008**, 5, 636-637	6.7	
289	Complex fractionated atrial electrograms: can they be made simple?. *Heart Rhythm*, **2008**, 5, 855-6	6.7	1
288	Inward rectifier-funny current balance and spontaneous automaticity: cautionary notes for biologic pacemaker development. *Heart Rhythm*, **2008**, 5, 1318-9	6.7	4
287	Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 62-73	6.4	704
286	Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. *Circulation*, **2008**, 117, 470-7	16.7	165
285	Atrial structural remodeling as an antiarrhythmic target. *Journal of Cardiovascular Pharmacology*, **2008**, 52, 4-10	3.1	46
284	Effects of heart disease on cardiac ion current density versus current amplitude: important conceptual subtleties in the language of arrhythmogenic ion channel remodeling. *Circulation Research*, **2008**, 102, 1298-300	15.7	10
283	Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. *Circulation*, **2008**, 117, 1630-41	16.7	201
282	Heat shock proteins as molecular targets for intervention in atrial fibrillation. *Cardiovascular Research*, **2008**, 78, 422-8	9.9	45
281	Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 93-102	6.4	205
280	Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H1489-504	5.2	56
279	Differential interactions of Na+ channel toxins with T-type Ca2+ channels. *Journal of General Physiology*, **2008**, 132, 101-13	3.4	18

278	Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. *Cardiovascular Research*, **2008**, 78, 63-70	9.9	54
277	Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. *Cardiovascular Research*, **2008**, 79, 61-9	9.9	45
276	Mechanisms underlying rate-dependent remodeling of transient outward potassium current in canine ventricular myocytes. *Circulation Research*, **2008**, 103, 733-42	15.7	68
275	Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. *Circulation Research*, **2008**, 103, 845-54	15.7	142
274	Feedback remodeling of cardiac potassium current expression: a novel potential mechanism for control of repolarization reserve. *Circulation*, **2008**, 118, 983-92	16.7	75
273	Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. *Journal of Cardiovascular Pharmacology*, **2008**, 52, 293-9	3.1	86
272	Distinct genomic replacements from Lewis correct diastolic dysfunction, attenuate hypertension, and reduce left ventricular hypertrophy in Dahl salt-sensitive rats. *Journal of Hypertension*, **2008**, 26, 1935-43	1.9	8
271	Atrial fibrillation: evidence for genetically determined disease. *Current Opinion in Cardiology*, **2008**, 23, 176-83	2.1	29
270	Case studies with the experts: management decisions in atrial fibrillation. *Journal of Cardiovascular Electrophysiology*, **2008**, 19 Suppl 1, S1-12; quiz S13-5	2.7	5
269	Changes in I K, ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. *Cardiovascular Research*, **2008**, 77, 35-43	9.9	69
268	Comparisons of Substrates Responsible for Atrial Versus Ventricular Fibrillation **2008**, 261-280		1
267	Cellular Electrophysiology and the Substrate for Atrial Fibrillation **2008**, 37-56		1
266	Protein kinase C, connexin43, and ischemic preconditioning: complex interactions of potential importance for controlling arrhythmias. *Heart Rhythm*, **2007**, 4, 1194-5	6.7	
265	Teasing out circadian variability in heart rate turbulence: A new approach to detecting biorhythms underlying cardiac function. *Heart Rhythm*, **2007**, 4, 301-3	6.7	1
264	Pulmonary vein reentry--properties and size matter: insights from a computational analysis. *Heart Rhythm*, **2007**, 4, 1553-62	6.7	74
263	Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. *Journal of Physiology*, **2007**, 582, 675-93	3.9	375
262	Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. *Journal of Physiology*, **2007**, 582, 1205-17	3.9	70
261	Atrial tachycardia induces remodelling of muscarinic receptors and their coupled potassium currents in canine left atrial and pulmonary vein cardiomyocytes. *British Journal of Pharmacology*, **2007**, 152, 1021-32	8.6	16

260	Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. *Physiological Reviews*, **2007**, 87, 425-56	47.9	621
259	Contrasting gene expression profiles in two canine models of atrial fibrillation. *Circulation Research*, **2007**, 100, 425-33	15.7	82
258	Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. *Cardiovascular Research*, **2007**, 74, 75-84	9.9	120
257	The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy. *Cardiovascular Research*, **2007**, 74, 104-13	9.9	34
256	Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. *Cardiovascular Research*, **2007**, 76, 442-52	9.9	114
255	Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. *Circulation*, **2007**, 116, 2101-9	16.7	113
254	Novel anti-arrhythmic drugs for atrial fibrillation management. *Current Vascular Pharmacology*, **2007**, 5, 185-95	3.3	21
253	Characterization of the cardiac KCNE1 gene promoter. *Cardiovascular Research*, **2007**, 73, 82-91	9.9	9
252	Adrenergic control of a constitutively active acetylcholine-regulated potassium current in canine atrial cardiomyocytes. *Cardiovascular Research*, **2007**, 74, 406-15	9.9	24
251	Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block. *Europace*, **2007**, 9, 869-74	3.9	32
250	Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 323, 916-23	4.7	41
249	Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. *Circulation*, **2007**, 115, 310-8	16.7	108
248	Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. *Journal of Molecular and Cellular Cardiology*, **2007**, 43, 223-9	5.8	124
247	The heart on a chip: the role of realistic mathematical models of cardiac electrical activity in understanding and treating cardiac arrhythmias. *Heart Rhythm*, **2007**, 4, 779-80	6.7	3
246	Electrophysiological Basis of Atrial Fibrillation **2007**, 18-3		
245	The Use of Cardiovascular Drugs: Pharmacological Principles **2007**, 35-39		
244	Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. *European Heart Journal*, **2006**, 27, 512-8	9.5	245
243	Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. *Cardiovascular Research*, **2006**, 69, 865-75	9.9	78

242	Comparison of Ca2+-handling properties of canine pulmonary vein and left atrial cardiomyocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 291, H2290-300	5.2	33
241	Potassium channel subunit remodeling in rabbits exposed to long-term bradycardia or tachycardia: discrete arrhythmogenic consequences related to differential delayed-rectifier changes. *Circulation* , **2006**, 113, 345-55	16.7	116
240	Induction of heat shock response protects the heart against atrial fibrillation. *Circulation Research*, **2006**, 99, 1394-402	15.7	137
239	Properties of a time-dependent potassium current in pig atrium: evidence for a role of kv1.5 in repolarization. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 319, 898-906	4.7	16
238	Involvement of lipid rafts and caveolae in cardiac ion channel function. *Cardiovascular Research*, **2006**, 69, 798-807	9.9	151
237	Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. *Circulation*, **2006**, 113, 1730-7	16.7	147
236	C-terminal domain of Kv4.2 and associated KChIP2 interactions regulate functional expression and gating of Kv4.2. *Journal of Biological Chemistry*, **2006**, 281, 27134-44	5.4	16
235	Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. *Genes and Development*, **2006**, 20, 2355-60	12.6	131
234	P3-17. *Heart Rhythm*, **2006**, 3, S183	6.7	8
233	Controversies in atrial fibrillation. *Lancet, The*, **2006**, 367, 262-72	40	142
232	Controversies in cardiology Authors' reply. *Lancet, The*, **2006**, 367, 1315-1316	40	5
231	Sex-based transmural differences in cardiac repolarization and ionic-current properties in canine left ventricles. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 291, H570-80	5.2	61
230	Ventricular tachyarrhythmia induction by strong cardiac shocks: can understanding underlying mechanisms lead to improved prevention of defibrillator failure?. *Heart Rhythm*, **2006**, 3, 596-7	6.7	
229	Inappropriate sinus tachycardia and beta-receptor autoantibodies: a mechanistic breakthrough?. *Heart Rhythm*, **2006**, 3, 1187-8	6.7	12
228	Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. *Journal of Molecular and Cellular Cardiology*, **2006**, 40, 173-84	5.8	65
227	Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. *Journal of Cardiovascular Pharmacology*, **2006**, 47, 123-32	3.1	40
226	Preoperative atrial cardiomyocyte ionic currents and postoperative AF: important insights into what is not the mechanism. *Journal of Cardiovascular Electrophysiology*, **2006**, 17, 1239-41	2.7	2
225	Innovative approaches to anti-arrhythmic drug therapy. *Nature Reviews Drug Discovery*, **2006**, 5, 1034-49	64.1	155

224	Aldosterone antagonism and atrial fibrillation: time for clinical assessment?. *European Heart Journal* , **2005**, 26, 2079-80	9.5	10
223	Specific potassium channel blockade for arrhythmia prevention in the ionically remodeled failing heart: peril or panacea?. *Heart Rhythm*, **2005**, 2, 739-40	6.7	1
222	Regional discrepancies in ionic currents and arrhythmia susceptibility: clinical relevance. *Heart Rhythm*, **2005**, 2, 177-8	6.7	
221	Pulmonary vein cellular electrophysiology and atrial fibrillation: does basic research help us understand clinical pulmonary-vein arrhythmogenesis?. *Heart Rhythm*, **2005**, 2, 1346	6.7	3
220	Combined parasympathetic-sympathetic nerve discharge and pulmonary vein afterdepolarizations: a new unifying concept with basic and clinical relevance. *Heart Rhythm*, **2005**, 2, 632-3	6.7	9
219	Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs. *Heart Rhythm*, **2005**, 2, S180	6.7	12
218	Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. *Biophysical Journal*, **2005**, 88, 3806-21	2.9	190
217	Are all sodium channel blockers created equal? Clinical-basic correlations based on observations in Brugada syndrome. *Heart Rhythm*, **2005**, 2, 261-2	6.7	4
216	The pathology of atrial fibrillation in dogs. *Journal of Veterinary Cardiology*, **2005**, 7, 121-9	1.9	29
215	Driver regions in atrial fibrillation associated with congestive heart failure: where are they, and what are they telling us?. *Journal of Cardiovascular Electrophysiology*, **2005**, 16, 1359-61	2.7	5
214	Mechanisms of atrial fibrillation: lessons from animal models. *Progress in Cardiovascular Diseases*, **2005**, 48, 9-28	8.5	170
213	Atrial cell action potential parameter fitting using genetic algorithms. *Medical and Biological Engineering and Computing*, **2005**, 43, 561-71	3.1	59
212	Atrial fibrillation: basic mechanisms, remodeling and triggers. *Journal of Interventional Cardiac Electrophysiology*, **2005**, 13, 181-93	2.4	72
211	Local delivery of 17beta-estradiol improves reendothelialization and decreases inflammation after coronary stenting in a porcine model. *Thrombosis and Haemostasis*, **2005**, 94, 1042-7	7	20
210	Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 289, H1002-12	5.2	88
209	Comparison of ion channel distribution and expression in cardiomyocytes of canine pulmonary veins versus left atrium. *Cardiovascular Research*, **2005**, 65, 104-16	9.9	76
208	Novel targets for cardiac antiarrhythmic drug development. *Current Pharmaceutical Design*, **2005**, 11, 1959-74	3.3	7
207	Functional expression of Kir2.x in human aortic endothelial cells: the dominant role of Kir2.2. *American Journal of Physiology - Cell Physiology*, **2005**, 289, C1134-44	5.4	51

206	Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifier current and membrane localization. *Cardiovascular Research*, **2005**, 67, 520-8	9.9	80
205	Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model. *Cardiovascular Research*, **2005**, 66, 472-81	9.9	130
204	Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. *Circulation Research*, **2005**, 96, e35-47	15.7	107
203	Atrial tachycardia remodeling of pulmonary vein cardiomyocytes: comparison with left atrium and potential relation to arrhythmogenesis. *Circulation*, **2005**, 111, 728-35	16.7	72
202	A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels. *Molecular Pharmacology*, **2005**, 68, 305-16	4.3	17
201	Arrhythmogenic right ventricular dysplasia type 1 and mutations in transforming growth factor beta3 gene regulatory regions: a breakthrough?. *Cardiovascular Research*, **2005**, 65, 302-4	9.9	4
200	Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 332-3		5
199	Wave block formation in homogeneous excitable media following premature excitations: dependence on restitution relations. *Physical Review E*, **2005**, 72, 031919	2.4	20
198	Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. *Circulation*, **2005**, 112, 471-81	16.7	188
197	Atrial Tachycardia, Flutter, and Fibrillation **2005**, 283-363		6
196	Mechanisms of atrial remodeling and clinical relevance. *Current Opinion in Cardiology*, **2005**, 20, 21-5	2.1	75
195	Atrial fibrillation: basic and clinical research at the Montreal Heart Institute. *Canadian Journal of Cardiology*, **2005**, 21, 1091-6	3.8	
194	Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. *Cellular Physiology and Biochemistry*, **2004**, 14, 31-40	3.9	42
193	Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. *Circulation*, **2004**, 110, 2313-9	16.7	223
192	Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?. *Cmaj*, **2004**, 171, 752-3	3.5	
191	Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. *Circulation*, **2004**, 109, 412-8	16.7	154
190	Defining "culprit mechanisms" in arrhythmogenic cardiac remodeling. *Circulation Research*, **2004**, 94, 1403-5	15.7	19
189	KvLQT1 modulates the distribution and biophysical properties of HERG. A novel alpha-subunit interaction between delayed rectifier currents. *Journal of Biological Chemistry*, **2004**, 279, 1233-41	5.4	57

188	Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. *Journal of Biological Chemistry*, **2004**, 279, 13289-92	5.4	105
187	Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure. *Circulation*, **2004**, 110, 1520-6	16.7	90
186	In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. *Cardiovascular Research*, **2004**, 61, 705-14	9.9	22
185	Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. *Cardiovascular Research*, **2004**, 63, 236-44	9.9	203
184	Potential mechanisms for the enhancement of HERG K+ channel function by phospholipid metabolites. *British Journal of Pharmacology*, **2004**, 141, 586-99	8.6	24
183	Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. *British Journal of Pharmacology*, **2004**, 142, 1300-8	8.6	82
182	Single-channel recordings of a rapid delayed rectifier current in adult mouse ventricular myocytes: basic properties and effects of divalent cations. *Journal of Physiology*, **2004**, 556, 401-13	3.9	25
181	Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. *Journal of Physiology*, **2004**, 557, 583-97	3.9	117
180	Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. *Journal of Physiology*, **2004**, 561, 735-48	3.9	122
179	The Kv4.2 N-terminal restores fast inactivation and confers KChIP2 modulatory effects on N-terminal-deleted Kv1.4 channels. *Pflugers Archiv European Journal of Physiology*, **2004**, 449, 235-47	4.6	7
178	Is atrial remodeling a viable target for prevention of atrial fibrillation recurrence?. *Journal of Cardiovascular Electrophysiology*, **2004**, 15, 885-6	2.7	2
177	Age, gender, and supraventricular arrhythmias: roles of ion channels, connexins, and tissue architecture?. *Heart Rhythm*, **2004**, 1, 397-8	6.7	7
176	Ionic current abnormalities associated with prolonged action potentials in cardiomyocytes from diseased human right ventricles. *Heart Rhythm*, **2004**, 1, 460-8	6.7	89
175	The effect of vagally induced dispersion of action potential duration on atrial arrhythmogenesis. *Heart Rhythm*, **2004**, 1, 334-44	6.7	69
174	The clinical relevance of connexin gating: how to control communication in the heart. *Heart Rhythm* , **2004**, 1, 234	6.7	4
173	Post-transcriptional alterations in the expression of cardiac Na+ channel subunits in chronic heart failure. *Journal of Molecular and Cellular Cardiology*, **2004**, 37, 91-100	5.8	60
172	Molecular basis of species-specific expression of repolarizing K+ currents in the heart. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 285, H1641-9	5.2	92
171	Barium block of Kir2 and human cardiac inward rectifier currents: evidence for subunit-heteromeric contribution to native currents. *Cardiovascular Research*, **2003**, 59, 328-38	9.9	96

170	Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. *Cardiovascular Research*, **2003**, 60, 315-25	9.9	183
169	Atrial ischemia promotes atrial fibrillation in dogs. *Circulation*, **2003**, 107, 1930-6	16.7	183
168	Canine ventricular KCNE2 expression resides predominantly in Purkinje fibers. *Circulation Research*, **2003**, 93, 189-91	15.7	57
167	Cost evaluation of rhythm control methods for atrial fibrillation: evidence from CTAF. *Journal of Interventional Cardiac Electrophysiology*, **2003**, 7, 211-4		2
166	Properties, expression and potential roles of cardiac K+ channel accessory subunits: MinK, MiRPs, KChIP, and KChAP. *Journal of Membrane Biology*, **2003**, 194, 141-52	2.3	52
165	Basic electrophysiology of the pulmonary veins and their role in atrial fibrillation: precipitators, perpetuators, and perplexers. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1372-5	2.7	52
164	Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, S133-9	2.7	26
163	Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 752-64	1.6	35
162	Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. *British Journal of Pharmacology*, **2003**, 138, 1475-84	8.6	20
161	Identification of atrial tissue in pulmonary veins using intravascular ultrasound. *Journal of the American Society of Echocardiography*, **2003**, 16, 982-7	5.8	21
160	Remodeling of cardiac inward-rectifier currents: an often-overlooked contributor to arrhythmogenic states. *Journal of Molecular and Cellular Cardiology*, **2003**, 35, 1395-8	5.8	3
159	Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity. *FEBS Letters*, **2003**, 534, 125-32	3.8	44
158	Tissue-specific expression of two human Ca(v)1.2 isoforms under the control of distinct 5' flanking regulatory elements. *FEBS Letters*, **2003**, 546, 349-54	3.8	42
157	Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. *Circulation*, **2003**, 107, 1440-6	16.7	132
156	Atrial electrophysiology and mechanisms of atrial fibrillation. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2003**, 8 Suppl 1, S5-11	2.6	45
155	Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. *Circulation*, **2003**, 108, 668-71	16.7	268
154	Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. *Journal of Physiology*, **2003**, 551, 801-13	3.9	184
153	Rhythm versus rate control for atrial fibrillation management: what recent randomized clinical trials allow us to affirm. *Cmaj*, **2003**, 168, 572-3	3.5	2

152	Prognostic significance of ventricular arrhythmias post-myocardial infarction. *Canadian Journal of Cardiology*, **2003**, 19, 1393-404	3.8	17
151	Differential distribution of Kir2.1 and Kir2.3 subunits in canine atrium and ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 283, H1123-33	5.2	72
150	Time-dependent transients in an ionically based mathematical model of the canine atrial action potential. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 282, H1437-51	5.2	55
149	A mathematical model of human atrioventricular nodal function incorporating concealed conduction. *Bulletin of Mathematical Biology*, **2002**, 64, 1083-99	2.1	28
148	Dofetilide block involves interactions with open and inactivated states of HERG channels. *Pflugers Archiv European Journal of Physiology*, **2002**, 443, 520-31	4.6	47
147	Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. *Journal of Cardiovascular Electrophysiology*, **2002**, 13, 399-405	2.7	164
146	A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. *Journal of Physiology*, **2002**, 540, 15-27	3.9	151
145	Kir2.4 and Kir2.1 K(+) channel subunits co-assemble: a potential new contributor to inward rectifier current heterogeneity. *Journal of Physiology*, **2002**, 544, 337-49	3.9	38
144	New ideas about atrial fibrillation 50 years on. *Nature*, **2002**, 415, 219-26	50.4	1125
143	Predicting the entrainment of reentrant cardiac waves using phase resetting curves. *Physical Review E*, **2002**, 65, 021908	2.4	33
142	Development of a computer algorithm for the detection of phase singularities and initial application to analyze simulations of atrial fibrillation. *Chaos*, **2002**, 12, 764-778	3.3	29
141	Consequences of atrial tachycardia-induced remodeling depend on the preexisting atrial substrate. *Circulation*, **2002**, 105, 251-7	16.7	64
140	Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. *Circulation Research*, **2002**, 90, E73-87	15.7	188
139	Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. *European Heart Journal*, **2002**, 23, 1050-6	9.5	21
138	Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. *Cardiovascular Research*, **2002**, 54, 456-61	9.9	180
137	Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. *Cardiovascular Research*, **2002**, 54, 438-46	9.9	61
136	Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 283, H1031-41	5.2	191
135	Cellular electrophysiology of atrial fibrillation. *Cardiovascular Research*, **2002**, 54, 259-69	9.9	46

134	Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. *Circulation*, **2002**, 105, 2672-8	16.7	195
133	Comparison of ion-channel subunit expression in canine cardiac Purkinje fibers and ventricular muscle. *Circulation Research*, **2002**, 91, 790-7	15.7	100
132	Properties of potassium currents in Purkinje cells of failing human hearts. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 283, H2495-503	5.2	33
131	Effects of sustained beta-adrenergic stimulation on ionic currents of cultured adult guinea pig cardiomyocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 282, H880-9	5.2	38
130	Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?. *Cardiovascular Research*, **2002**, 54, 347-60	9.9	70
129	Remodeling of Ca(2+)-handling by atrial tachycardia: evidence for a role in loss of rate-adaptation. *Cardiovascular Research*, **2002**, 54, 416-26	9.9	32
128	Ultrarapid delayed rectifier K(+) current in H9c2 rat ventricular cell line: biophysical property and molecular identity. *Cellular Physiology and Biochemistry*, **2002**, 12, 215-26	3.9	7
127	Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. *Circulation Research*, **2002**, 90, 939-50	15.7	330
126	New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. *Drugs* , **2002**, 62, 2377-97	12.1	54
125	New insights into the mechanisms and management of atrial fibrillation. *Cmaj*, **2002**, 167, 1012-20	3.5	13
124	HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. *Cancer Research*, **2002**, 62, 4843-8	10.1	151
123	Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. *Cardiovascular Research*, **2001**, 49, 751-61	9.9	86
122	Sodium channel inactivation abnormalities associated with heart disease: ionic remodeling and arrhythmogenic channelopathies. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 226-8	2.7	1
121	Method for simultaneous epicardial and endocardial mapping of in vivo canine heart: application to atrial conduction properties and arrhythmia mechanisms. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 548-55	2.7	69
120	. *Journal of Interventional Cardiac Electrophysiology*, **2001**, 5, 263-267		
119	. *Journal of Interventional Cardiac Electrophysiology*, **2001**, 5, 162-165		1
118	Arrhythmogenic ionic remodeling: adaptive responses with maladaptive consequences. *Trends in Cardiovascular Medicine*, **2001**, 11, 295-301	6.9	24
117	Oxidative preconditioning and apoptosis in L-cells. Roles of protein kinase B and mitogen-activated protein kinases. *Journal of Biological Chemistry*, **2001**, 276, 26357-64	5.4	61

116	Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. *Circulation*, **2001**, 104, 2608-14	16.7	554
115	Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. *Cardiovascular Research*, **2001**, 49, 762-70	9.9	70
114	Phospholipid metabolite 1-palmitoyl-lysophosphatidylcholine enhances human ether-a-go-go-related gene (HERG) K(+) channel function. *Circulation*, **2001**, 104, 2645-8	16.7	32
113	Potential ionic mechanism for repolarization differences between canine right and left atrium. *Circulation Research*, **2001**, 88, 1168-75	15.7	143
112	Ionic remodeling of cardiac Purkinje cells by congestive heart failure. *Circulation*, **2001**, 104, 2095-100	16.7	85
111	The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF. *Cardiovascular Research*, **2001**, 50, 75-84	9.9	15
110	Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs. *Cardiovascular Research*, **2001**, 50, 85-96	9.9	20
109	Coronary artery endothelial protection after local delivery of 17beta-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. *Journal of the American College of Cardiology*, **2001**, 38, 1570-6	15.1	47
108	Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. *American Journal of Physiology - Heart and Circulatory Physiology*, **2001**, 280, H1075-80	5.2	57
107	Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. *Molecular Pharmacology*, **2001**, 59, 1029-36	4.3	94
106	Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. *Cardiovascular Research*, **2001**, 52, 217-25	9.9	79
105	Molecular evidence for a role of Shaw (Kv3) potassium channel subunits in potassium currents of dog atrium. *Journal of Physiology*, **2000**, 527 Pt 3, 467-78	3.9	26
104	State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes. *Journal of Physiology*, **2000**, 526 Pt 2, 265-78	3.9	18
103	Mechanisms of Antiarrhythmic Drug Actions. *Journal of Interventional Cardiac Electrophysiology*, **2000**, 4, 186-189		
102	Amiodarone Oral. *Journal of Interventional Cardiac Electrophysiology*, **2000**, 4, 262-269		1
101	A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H466-74	5.2	33
100	Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H1767-85	5.2	103
99	Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. *New England Journal of Medicine*, **2000**, 342, 913-20	59.2	864

98	Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. *Circulation*, **2000**, 101, 955-61	16.7	12
97	Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. *Circulation Research*, **2000**, 87, 440-7	15.7	118
96	Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs : potential relevance to ionic mechanisms in vivo. *Circulation*, **2000**, 101, 1179-84	16.7	36
95	Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. *Circulation*, **2000**, 102, 104-12	16.7	87
94	Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. *Cardiovascular Research*, **2000**, 46, 151-61	9.9	20
93	Nicotine is a potent blocker of the cardiac A-type K(+) channels. Effects on cloned Kv4.3 channels and native transient outward current. *Circulation*, **2000**, 102, 1165-71	16.7	80
92	Effects of experimental heart failure on atrial cellular and ionic electrophysiology. *Circulation*, **2000**, 101, 2631-8	16.7	317
91	Basic mechanisms of atrial fibrillation--very new insights into very old ideas. *Annual Review of Physiology*, **2000**, 62, 51-77	23.1	137
90	Azimilide. *Drugs*, **2000**, 59, 279-278	12.1	1
89	Oita International Electrocardiology Symposium 2000 Electrophysiology and Management of Lethal Arrhythmias in the New Millennium: From Genes to Bedside *Japanese Journal of Electrocardiology*, **2000**, 20, 6-10	0	
88	Electrophysiological mechanisms by which hypothyroidism delays repolarization in guinea pig hearts. *American Journal of Physiology - Heart and Circulatory Physiology*, **1999**, 277, H211-20	5.2	13
87	Transmembrane ICa contributes to rate-dependent changes of action potentials in human ventricular myocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **1999**, 276, H98-H106	5.2	54
86	Dihydropyridine and beta adrenergic receptor binding in dogs with tachycardia-induced atrial fibrillation. *Cardiovascular Research*, **1999**, 42, 434-42	9.9	32
85	Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation. *Cardiovascular Research*, **1999**, 42, 298-308	9.9	88
84	Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. *Circulation Research*, **1999**, 84, 776-84	15.7	279
83	Ionic determinants of atrial fibrillation and Ca2+ channel abnormalities : cause, consequence, or innocent bystander?. *Circulation Research*, **1999**, 85, 473-6	15.7	42
82	Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. *Circulation*, **1999**, 99, 30-5	16.7	125
81	Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. *Circulation Research*, **1999**, 84, 551-61	15.7	172

80	Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation*, **1999**, 100, 87-95	16.7	1094
79	Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. *Cardiovascular Research*, **1999**, 42, 477-89	9.9	196
78	The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. *Circulation*, **1999**, 100, 2191-7	16.7	123
77	Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes. *Journal of Physiology*, **1999**, 516 (Pt 2), 385-98	3.9	26
76	Electrophysiologic remodeling: are ion channels static players or dynamic movers?. *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 1553-6	2.7	33
75	The molecular and ionic specificity of antiarrhythmic drug actions. *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 272-82	2.7	77
74	Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 472-81	2.7	18
73	The Pathophysiology of Atrial Fibrillation. *Journal of Interventional Cardiac Electrophysiology*, **1999**, 3, 85-87		
72	Atrial Fibrillation: Experimental and Theoretical Developments. *Journal of Interventional Cardiac Electrophysiology*, **1999**, 3, 110-112		
71	Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. *American Journal of Cardiology*, **1999**, 84, 11R-19R	3	204
70	Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity. *Cellular Physiology and Biochemistry*, **1999**, 9, 217-26	3.9	113
69	Is there a future for antiarrhythmic drug therapy?. *Drugs*, **1998**, 56, 767-81	12.1	20
68	Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. *Cardiovascular Research*, **1998**, 37, 567-77	9.9	47
67	Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. *Circulation*, **1998**, 98, 719-27	16.7	159
66	Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. *Circulation Research*, **1998**, 83, 541-51	15.7	148
65	Effects of the diuretic agent indapamide on Na+, transient outward, and delayed rectifier currents in canine atrial myocytes. *Circulation Research*, **1998**, 83, 158-66	15.7	22
64	Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. *Circulation*, **1998**, 98, 2202-9	16.7	267
63	Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. *Circulation*, **1998**, 98, 2422-8	16.7	182

62	Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. *Cardiovascular Research*, **1998**, 38, 441-50	9.9	175
61	Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. *Cardiovascular Research*, **1998**, 37, 627-35	9.9	63
60	Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. *American Journal of Physiology - Heart and Circulatory Physiology*, **1998**, 275, H301-21	5.2	504
59	Characterization of a transient outward K+ current with inward rectification in canine ventricular myocytes. *American Journal of Physiology - Cell Physiology*, **1998**, 274, C577-85	5.4	243
58	Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. *American Journal of Physiology - Heart and Circulatory Physiology*, **1998**, 275, H1717-25	5.2	34
57	Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalinization in human cardiac myocytes. *Cardiovascular Research*, **1998**, 38, 395-404	9.9	30
56	Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. *New England Journal of Medicine*, **1997**, 337, 365-72	59.2	514
55	Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. *Journal of Cardiovascular Electrophysiology*, **1997**, 8, 469-80	2.7	46
54	Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). *American Journal of Cardiology*, **1997**, 80, 464-8	3	30
53	Atrial Fibrillation: Experimental and Theoretical Developments. *Journal of Interventional Cardiac Electrophysiology*, **1997**, 1, 49-51		
52	The Pathophysiology of Atrial Fibrillation. *Journal of Interventional Cardiac Electrophysiology*, **1997**, 1, 25-26		
51	Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. *Circulation*, **1997**, 96, 4027-35	16.7	241
50	Evidence that outwardly rectifying Cl- channels underlie volume-regulated Cl- currents in heart. *Circulation Research*, **1997**, 80, 103-13	15.7	56
49	Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. *Circulation Research*, **1997**, 80, 572-9	15.7	225
48	Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. *Circulation Research*, **1997**, 81, 512-25	15.7	475
47	Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. *Circulation Research*, **1997**, 81, 1045-52	15.7	148
46	Demonstration of an inward Na(+)-Ca2+ exchange current in adult human atrial myocytes. *Annals of the New York Academy of Sciences*, **1996**, 779, 525-8	6.5	9
45	Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug-induced sodium channel blockade by sodium bicarbonate. *Circulation*, **1996**, 94, 1954-61	16.7	46

44	Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. *Circulation Research*, **1996**, 78, 492-8	15.7	113
43	Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. *Circulation Research*, **1996**, 78, 689-96	15.7	326
42	Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. *Circulation Research*, **1996**, 78, 903-15	15.7	109
41	Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. *Journal of Nuclear Cardiology*, **1995**, 2, 3-17	2.1	125
40	Long-term risk stratification with dipyridamole imaging. *American Heart Journal*, **1995**, 129, 880-6	4.9	30
39	Newer developments in the management of atrial fibrillation. *American Heart Journal*, **1995**, 130, 1094-1106	4.9	75
38	Idiopathic atrial fibrillation in dogs: electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide. *Journal of the American College of Cardiology*, **1995**, 26, 277-86	15.1	45
37	Is cardiac migraine a clinical entity?. *Clinical Nuclear Medicine*, **1995**, 20, 403-6	1.7	
36	Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. *Circulation*, **1995**, 92, 1300-11	16.7	26
35	Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. *Circulation*, **1995**, 92, 2259-65	16.7	89
34	Alpha-adrenergic control of volume-regulated Cl- currents in rabbit atrial myocytes. Characterization of a novel ionic regulatory mechanism. *Circulation Research*, **1995**, 77, 379-93	15.7	69
33	Rapid and slow components of delayed rectifier current in human atrial myocytes. *Cardiovascular Research*, **1994**, 28, 1540-6	9.9	177
32	Absence of pharmacokinetic interaction between amiodarone and lidocaine. *American Journal of Cardiology*, **1994**, 73, 92-4	3	5
31	Dynamic behavior of the atrioventricular node: a functional model of interaction between recovery, facilitation, and fatigue. *Journal of Cardiovascular Electrophysiology*, **1994**, 5, 90-102	2.7	26
30	The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. *Drugs*, **1994**, 48, 345-71	12.1	51
29	Antiarrhythmic prophylaxis after acute myocardial infarction. Is lidocaine still useful?. *Drugs*, **1993**, 45, 9-14	12.1	5
28	Comparative mechanisms of action of antiarrhythmic drugs. *American Journal of Cardiology*, **1993**, 72, 13F-17F	3	25
27	Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. *Journal of Cardiovascular Electrophysiology*, **1992**, 3, 266-280	2.7	30

26	Effects of flecainide on the rate dependence of atrial refractoriness, atrial repolarization and atrioventricular node conduction in anesthetized dogs. *Journal of the American College of Cardiology*, **1992**, 19, 1335-42	15.1	22
25	Multivariate clinical models and quantitative dipyridamole-thallium imaging to predict cardiac morbidity and death after vascular reconstruction. *Journal of Vascular Surgery*, **1991**, 14, 160-9	3.5	70
24	Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance. *Drugs*, **1991**, 41, 672-701	12.1	58
23	Pharmacologic response of cesium-induced ventricular tachyarrhythmias in anesthetized dogs. *Journal of Cardiovascular Pharmacology*, **1990**, 15, 552-61	3.1	15
22	Cycle length alternation during supraventricular tachycardia: occurrence and mechanism in a canine model of AV reentrant tachycardia. *PACE - Pacing and Clinical Electrophysiology*, **1990**, 13, 314-25	1.6	8
21	Electrophysiological effects of alpha-adrenergic stimulation. *PACE - Pacing and Clinical Electrophysiology*, **1990**, 13, 578-82	1.6	15
20	Determinants and significance of diltiazem plasma concentrations after acute myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. *American Journal of Cardiology*, **1990**, 66, 1422-8	3	5
19	What is an antiarrhythmic drug? From clinical trials to fundamental concepts. *American Journal of Cardiology*, **1990**, 66, 96-9	3	17
18	Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. *American Journal of Medicine*, **1990**, 89, 235-8	2.4	95
17	Attenuation of class 3 and sinus node effects of amiodarone by experimental hypothyroidism. *Journal of Cardiovascular Pharmacology*, **1989**, 13, 447-50	3.1	15
16	Sinus node dysfunction and sudden cardiac death following treatment with encainide. *PACE - Pacing and Clinical Electrophysiology*, **1989**, 12, 1607-12	1.6	3
15	Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. *Journal of the American College of Cardiology*, **1989**, 13, 1190-4	15.1	40
14	Recent advances in understanding the pharmacology of amiodarone. *Drugs*, **1988**, 36, 121-31	12.1	38
13	Bevantolol disposition in patients with hepatic cirrhosis. *Journal of Clinical Pharmacology*, **1987**, 27, 962-6	2.9	2
12	Effect of frequent ventricular ectopy on myocardial infarct size in dogs. *Cardiovascular Research*, **1987**, 21, 286-92	9.9	3
11	Effects of taurine depletion on rat cardiac electrophysiology: in vivo and in vitro studies. *Life Sciences*, **1987**, 40, 997-1005	6.8	27
10	The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction. *Clinical Pharmacokinetics*, **1987**, 13, 293-316	6.2	36
9	Relationship between an arrhythmogenic action of lidocaine and its effects on excitation patterns in acutely ischemic porcine myocardium. *Journal of Cardiovascular Pharmacology*, **1986**, 8, 126-36	3.1	31

8	Effects of encainide on the inducibility of ventricular arrhythmia in normal anesthetized dogs. *Journal of Tongji Medical University*, **1986**, 6, 60-6		
7	Age-dependent lidocaine disposition in patients with acute myocardial infarction. *Clinical Pharmacology and Therapeutics*, **1985**, 37, 381-6	6.1	29
6	Lidocaine problems in understanding an antiarrhythmic drug. *Trends in Pharmacological Sciences*, **1982**, 3, 297-300	13.2	1
5	Use of excessive lidocaine concentrations for local anestheisa. *New England Journal of Medicine*, **1980**, 302, 122	59.2	4
4	Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. *American Journal of Cardiology*, **1980**, 45, 627-32	3	66
3	Therapeutic blood lidocaine concentrations after local anesthesia for cardiac electrophysiologic studies. *New England Journal of Medicine*, **1979**, 301, 418-20	59.2	43
2	Cholesterol Regulation of Cardiac Ion Channels91-107		
1	Transcriptomic profiling of atrial fibrillation canine models at disease onset		1